These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24163380)

  • 1. The role of cell density and intratumoral heterogeneity in multidrug resistance.
    Lavi O; Greene JM; Levy D; Gottesman MM
    Cancer Res; 2013 Dec; 73(24):7168-75. PubMed ID: 24163380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of cell density and mutations in a model of multidrug resistance in solid tumors.
    Greene J; Lavi O; Gottesman MM; Levy D
    Bull Math Biol; 2014 Mar; 76(3):627-53. PubMed ID: 24553772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth.
    Cho H; Levy D
    J Theor Biol; 2018 Jan; 436():120-134. PubMed ID: 29030212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
    Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
    Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro tumor microenvironment models containing physical and biological barriers for modelling multidrug resistance mechanisms and multidrug delivery strategies.
    Rahmanian M; Seyfoori A; Ghasemi M; Shamsi M; Kolahchi AR; Modarres HP; Sanati-Nezhad A; Majidzadeh-A K
    J Control Release; 2021 Jun; 334():164-177. PubMed ID: 33895200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the Dynamics of Heterogeneity of Solid Tumors in Response to Chemotherapy.
    Cho H; Levy D
    Bull Math Biol; 2017 Dec; 79(12):2986-3012. PubMed ID: 29022203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors.
    Lorz A; Lorenzi T; Clairambault J; Escargueil A; Perthame B
    Bull Math Biol; 2015 Jan; 77(1):1-22. PubMed ID: 25480478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dynamics of drug resistance: a mathematical perspective.
    Lavi O; Gottesman MM; Levy D
    Drug Resist Updat; 2012; 15(1-2):90-7. PubMed ID: 22387162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing intra-tumoral heterogeneity and therapy resistance.
    Rybinski B; Yun K
    Oncotarget; 2016 Nov; 7(44):72322-72342. PubMed ID: 27608848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral Heterogeneity: From Diversity Comes Resistance.
    Pribluda A; de la Cruz CC; Jackson EL
    Clin Cancer Res; 2015 Jul; 21(13):2916-23. PubMed ID: 25838394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.
    Broxterman HJ; Gotink KJ; Verheul HM
    Drug Resist Updat; 2009; 12(4-5):114-26. PubMed ID: 19648052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a Better Understanding of the Complexity of Cancer Drug Resistance.
    Gottesman MM; Lavi O; Hall MD; Gillet JP
    Annu Rev Pharmacol Toxicol; 2016; 56():85-102. PubMed ID: 26514196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy and multidrug resistance in cancer.
    Li YJ; Lei YH; Yao N; Wang CR; Hu N; Ye WC; Zhang DM; Chen ZS
    Chin J Cancer; 2017 Jun; 36(1):52. PubMed ID: 28646911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of acquired resistance to anti-cancer therapy.
    Foo J; Michor F
    J Theor Biol; 2014 Aug; 355():10-20. PubMed ID: 24681298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling intrinsic heterogeneity and growth of cancer cells.
    Greene JM; Levy D; Fung KL; Souza PS; Gottesman MM; Lavi O
    J Theor Biol; 2015 Feb; 367():262-277. PubMed ID: 25457229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.